Lv3
358 积分 2021-01-04 加入
Primary resistance to icotinib in a patient with lung adenocarcinoma harboring EGFR L858R and Q787k mutations
1天前
待确认
Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods
15天前
已完结
Furmonertinib and intrathecal pemetrexed chemotherapy rechallenges osimertinib-refractory leptomeningeal metastasis in a non-small cell lung cancer patient harboring EGFR20 R776S, C797S, and EGFR21 L858R compound EGFR mutations: a case report
4个月前
已完结
[Expert consensus on homologous recombination repair gene testing and variant interpretation in prostate cancer]
5个月前
已完结
[Clinical pathological expert consensus on HER-2 testing in urothelial carcinoma in China]
5个月前
已完结
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer
5个月前
已完结
Hyperprogression during immunotherapy
6个月前
已完结
Rapid Advances in Resectable Non–Small Cell Lung Cancer
6个月前
已完结
Complete response to first-line osimertinib monotherapy in a complex epidermal growth factor receptor mutant (L833V/H835L) lung adenocarcinoma patient: a case report
8个月前
已完结
Brief Report: EGFR L833V/H835L Duplex-Mutated NSCLC With Leptomeningeal Carcinomatosis Responsive to Osimertinib
8个月前
已完结
皖公网安备34019202002308
